Labiotech: Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B
Labiotech: Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B
Labiotech: Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series Bhttps://eyevensys.com/wp-content/themes/crocal/images/empty/thumbnail.jpg150150EyevensysEyevensyshttps://eyevensys.com/wp-content/themes/crocal/images/empty/thumbnail.jpg
Patricia Zilliox, CEO of Eyevensys speaks about raising €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness.